Omega Funds is a leading international investment firm that creates and invests in life sciences companies that target our world’s most urgent medical needs.
Artios is a leading DNA Damage Response (DDR) company exploiting a broad DDR-based platform and small molecule drug discovery capabilities to develop a diverse pipeline of product candidates for the treatment of cancer.
The funding propels Artios’ ability to progress beyond synthetic lethality and to continue the exploitation of the full spectrum of oncology vulnerabilities presented by the DDR through deployment of Artios’ DDR-based platform and small molecule drug discovery capabilities. It also supports expansion of potentially best-in-class ATR inhibitor and first-in-class highly selective Polθ inhibitor programs by enabling clinical development in multiple tumor settings and biological backgrounds of single agent and combination therapies.
The financing was co-led by TCG X. Additional investors include Avidity Partners, Invus, Deep Track Capital, Sofinnova Partners, Tetragon Financial Group, RTW Investments LP, Soleus Capital, Piper Heartland Healthcare Capital, CaaS Capital Management, Schroders Capital, Arix Bioscience plc, SV Health Investors, Andera Partners, LSP (Life Sciences Partners), M Ventures, Pfizer Ventures, IP Group plc, and Novartis Venture Fund.
The Goodwin team was led by Sophie McGrath, Maria Dragun, and Heidi Fitchett (Corporate, London), and included John Egan and Carolyn Nguyen (Corporate, U.S.); Duncan Greenhalgh and Miho Kaneko (Intellectual Property); and Tim Worden, Gretchen Scott, Georgia Powell, Lucy Sharples, Curtis McCluskey, Jacqueline Klosek, Federica De Santis, and Joseph McGurrin (Data, Privacy & Cybersecurity); with assistance from Robert Young (Tax) and Bibek Pandey (ERISA & Executive Compensation).
For more details, read the press release.